BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15867365)

  • 1. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
    Ogushi T; Takahashi S; Takeuchi T; Urano T; Horie-Inoue K; Kumagai J; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
    Cancer Res; 2005 May; 65(9):3700-6. PubMed ID: 15867365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer.
    Fujimura T; Takahashi S; Urano T; Xiaoqiang L; Ogushi T; Muramatsu M; Ouchi Y; Kitamura T; Homma Y; Inoue S
    Int J Urol; 2009 Mar; 16(3):329-32. PubMed ID: 19207611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBAG9 is a tumor-promoting and prognostic factor for bladder cancer.
    Kumagai J; Urano T; Ogushi T; Takahashi S; Horie-Inoue K; Fujimura T; Azuma K; Muramatsu M; Ouchi Y; Kitamura T; Inoue S
    Int J Cancer; 2009 Feb; 124(4):799-805. PubMed ID: 19030177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region.
    Maeyama Y; Otsu M; Kubo S; Yamano T; Iimura Y; Onodera M; Kondo S; Sakiyama Y; Ariga T
    Int J Oncol; 2011 Jul; 39(1):41-9. PubMed ID: 21573489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
    Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential.
    Miyake H; Hara I; Yoshimura K; Eto H; Arakawa S; Wada S; Chihara K; Kamidono S
    Cancer Res; 1996 May; 56(10):2440-5. PubMed ID: 8625325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma.
    Hong X; Liu Y; Hu G; Zhao D; Shen J; Shen F; Cao X; Wang Q
    Cancer Sci; 2009 May; 100(5):961-9. PubMed ID: 19445026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
    Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
    Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
    Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
    Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
    Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
    Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
    Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
    Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
    Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
    Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor site-dependent differential modulation of systemic immunity in RENCA bearing mice.
    Yoon HL; Choi KM; Jung YS; Park CH; Yoon SS
    In Vivo; 1999; 13(5):407-13. PubMed ID: 10654194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
    Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.